N/A
Completed N=4,182
PLATINUM Diversity
Source: ClinicalTrials.gov NCT02240810 ↗Enrolled (actual)
4,182
Serious AEs
10.3%
Results posted
May 2019
Primary outcomePrimary: Composite Rate of Death, Myocardial Infarction (MI), and Target Vessel Revascularization (TVR) — 128; 120; 155; 99 Participants
Summary
To compile acute procedural performance and clinical outcomes data for the Promus PREMIER everolimus-eluting coronary stent system in understudied/underserved patient populations including women and minorities.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite Rate of Death, Myocardial Infarction (MI), and Target Vessel Revascularization (TVR) |
128; 120; 155; 99 | — |
| SECONDARY Death |
60; 35; 62; 38 | — |
| SECONDARY Myocardial Infarction (MI) |
38; 17; 34; 32 | — |
| SECONDARY Target Vessel Revascularization (TVR) |
58; 86; 84; 56 | — |
Eligibility Criteria
Inclusion Criteria
- Patient must be at least 18 years of age
- Patient must sign informed consent form
- Patient has received at least one Promus PREMIER stent
- Patient self-identifies as one or more of the following:
- Female
- Black of African Heritage
- Hispanic/Latino
- American Indian or Alaska native
Exclusion Criteria
- Not applicable
Data sourced from ClinicalTrials.gov (NCT02240810). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.